Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

Lupron Depot (leuprolide acetate for depot suspension)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1996

Specific Treatments:

prostate cancer

General Information

A three month, 22.5 mg dosage of Lupron Depot was approved as a treatment for advanced-stage prostate cancer.

Clinical Results

In clinical trials, the safety and efficacy of Lupron Depot (three month, 22.5 mg) were similar to that of the original daily subcutaneous injection and the monthly depot formulation.

Side Effects

The most common side effect reported was hot flashes (58.5%). Like other treatment options, it may also cause impotence.

Mechanism of Action

Lupron Depot (three month, 22.5 mg) works by shutting down the production of the hormone testosterone, which plays a significant role in the growth of prostate cancer. Decreasing the levels of testosterone in the body also alleviates the bone pain and urinary problems that may be associated with metastatic prostate cancer.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation